Similar Search Results

Advertising Regulations in Pharmaceutical Markets : Product versus Enlightenment

Ishida, Junichiro - 2019

This paper analyzes the optimal content regulation of direct-to-consumer advertisement (DTCA) in a pharmaceutical market, with particular focus on the distinction between product and enlightenment advertisement. Firms are allowed to freely promote their own specific products under product DTCA,...

Persistent link: https://www.econbiz.de/10012897821

Lo, Andrew W. - 2020

Current business models have struggled to support early-stage drug development. In this paper, we study an alternative financing model, the mega-fund structure, to fund drug discovery. We extend the framework proposed in previous studies to account for correlation between phase transitions in...

Persistent link: https://www.econbiz.de/10012822897

The Effect of Medical Cannabis Laws on Pharmaceutical Marketing to Physicians

Lebesmuehlbacher, Thomas - 2020

Although cannabis is federally prohibited, a majority U.S. states have implemented medical cannabis laws (MCLs). As more individuals consider the drug for medical treatment, they potentially substitute away from prescription drugs. Therefore, an MCL signals competitor entry. This paper exploits...

Persistent link: https://www.econbiz.de/10012826586

State Pharmaceutical Importation Programs : An Analysis of the Cost Effectiveness

Acri née Lybecker, Kristina M.L. - 2019

West Virginia aims to reduce spending on pharmaceuticals by importing them from Canada. To examine the cost effectiveness …

Persistent link: https://www.econbiz.de/10012868596

Pharmaceutical Opioid Marketing and Physician Prescribing Behavior

Beilfuss, Svetlana - 2019

Physicians' relationships with the pharmaceutical industry have recently come under public scrutiny, particularly in the context of opioid drug prescribing. This study examines the effect of doctor-industry marketing interactions on subsequent prescribing patterns of opioids using linked...

Persistent link: https://www.econbiz.de/10012871515

Pharmacy Benefit Managers and Generic Pharmaceuticals Pricing Conspiracy : Unveiling Lock-In Mechanisms, Structural Shortcomings and Antitrust Evidence

Yoo, Kwanghyuk David - 2019

Titanic-scale multistate generic pricing antitrust litigation has been underway since December 2016, increasingly involving a myriad of generic drug manufacturers and drugs. Forty-seven states allege a pricing conspiracy wherein twenty defendants participated in a multitude of specific...

Persistent link: https://www.econbiz.de/10012871612

Externalities of National Pharmaceutical Policy when Markets are Integrated through Parallel Trade

Birg, Laura - 2017

This paper studies externalities of nationally determined cost-sharing systems, in particular coinsurance rates (patients pay a percentage of the price), under pharmaceutical parallel trade in a two-country model with a vertical distributor relationship. Parallel trade generates a...

Persistent link: https://www.econbiz.de/10012973688

Medical Provider Agency and Pharmaceutical Demand with Universal Coverage : Evidence from Taiwan

Tang, Meng-Chi - 2016

Medical providers' profit considerations might take priority over their patients' needs in Taiwan because they are allowed to both dispense and prescribe medications. I examine this problem in the demand of the anti-diabetic drugs market using information from millions of claims. Empirical...

Persistent link: https://www.econbiz.de/10012979012

Free Movement and Competition in the European Market for Pharmaceuticals

Caro de Sousa, Pedro - 2016

.This chapter will provide an overview of free movement cases on pharmaceuticals, with a view to frame such case law within the … section will provide an overview of the structure of the European market for pharmaceuticals, including the basic European … regulatory framework; a second section will review the case law on free movement and pharmaceuticals; and a last section will …

Persistent link: https://www.econbiz.de/10012980141

Prescription Drug Insurance Plans : Potential Cost Reductions and the Pass-Through of Manufacturer Pharmaceutical Rebates to Premiums

Yang, Charles C. - 2019

In response to the recent moves to reduce prescription drug expenses and eliminate manufacturer pharmaceutical rebates for Medicare and Medicaid, this research investigates the pass-through of manufacturer pharmaceutical rebates to premiums and examines the potential prescription drug cost...

Persistent link: https://www.econbiz.de/10012859130